Recent Updates
Recently added Catalysts
NVAX Positive Sentiment Score: 70/100

Novavax to Participate in TD Cowen

Key Takeaway: Novavax, Inc. will participate in TD Cowen's 43rd Annual Health Care Conference on March 8, 2023. The event will feature a fireside chat with Novavax's Chief Commercial Officer, John Trizzino, and will provide insights into the company's advancements in vaccine technology. A recorded version of the session will be available on the company's website for 90 days following the conference. This participation underscores Novavax's ongoing dedication to combating serious infectious diseases through innovative vaccines.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a significant healthcare conference demonstrates industry engagement.
  • Opportunity for investors to hear directly from company leaders.
  • Showcases Novavax's commitment to vaccine development and innovation.

Full Press Release Details

GAITHERSBURG, Md., March 6, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in TD Cowen's 43rd Annual Health Care Conference.
Conference Details:
Fireside Chat
Date: Wednesday, March 8, 2023
Time: 9:50 – 10:20 a.m. Eastern Standard Time (EST)
Location: Boston Marriott Copley Place in Boston, Massachusetts
Moderator: Georgi Yordanov, Equity Research Analyst – Biotechnology
Novavax participant: John Trizzino, Chief Commercial Officer and Chief Business Officer
Conference
Event: Investor Meetings
Date: Wednesday, March 8, 2023
A replay of the recorded fireside session will be available through the Events & presentations page of the Company's website at ir.novavax.com for 90 days from the date of the conference.
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.
SOURCE Novavax, Inc.

21 %

more press release views with

Frequently Asked Questions

When is Novavax participating in the Health Care Conference?

Novavax will participate in the conference on March 8, 2023.

Where is the TD Cowen Health Care Conference held?

The conference takes place at Boston Marriott Copley Place in Boston, MA.

Who will represent Novavax at the conference?

John Trizzino, the Chief Commercial Officer, will represent Novavax.

How long will the fireside chat replay be available?

The replay will be accessible for 90 days after the conference.

What type of vaccines does Novavax develop?

Novavax develops protein-based vaccines targeting serious infectious diseases.

Last updated: Mar 6, 2023